Literature DB >> 16407130

A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis.

Melanie J Percy1, Quan Zhao, Adrian Flores, Claire Harrison, Terence R J Lappin, Patrick H Maxwell, Mary Frances McMullin, Frank S Lee.   

Abstract

The number of red blood cells is normally tightly regulated by a classic homeostatic mechanism based on oxygen sensing in the kidney. Decreased oxygen delivery resulting from anemia induces the production of erythropoietin, which increases red cell production and hence oxygen delivery. Investigations of erythropoietin regulation identified the transcription factor hypoxia-inducible factor (HIF). HIF is now recognized as being a key regulator of genes that function in a comprehensive range of processes besides erythropoiesis, including energy metabolism and angiogenesis. HIF itself is regulated through the alpha-subunit, which is hydroxylated in the presence of oxygen by a family of three prolyl hydroxylase domain proteins (PHDs)/HIF prolyl hydroxylases/egg-laying-defective nine enzymes. Hydroxylation allows capture by the von Hippel-Lindau tumor suppressor gene product, ubiquitination, and destruction by the proteasome. Here we describe an inherited mutation in a mammalian PHD enzyme. We show that this mutation in PHD2 results in a marked decrease in enzyme activity and is associated with familial erythrocytosis, identifying a previously unrecognized cause of this condition. Our findings indicate that PHD2 is critical for normal regulation of HIF in humans.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16407130      PMCID: PMC1334658          DOI: 10.1073/pnas.0508423103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

1.  Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice.

Authors:  Erinn B Rankin; Debra F Higgins; Jacqueline A Walisser; Randall S Johnson; Christopher A Bradfield; Volker H Haase
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

2.  VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1alpha.

Authors:  Zaibo Li; Dakun Wang; Edward M Messing; Guan Wu
Journal:  EMBO Rep       Date:  2005-04       Impact factor: 8.807

3.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

4.  Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene.

Authors:  G L Semenza; M K Nejfelt; S M Chi; S E Antonarakis
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

5.  Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha.

Authors:  A Y Yu; L A Shimoda; N V Iyer; D L Huso; X Sun; R McWilliams; T Beaty; J S Sham; C M Wiener; J T Sylvester; G L Semenza
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

6.  HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner.

Authors:  Marzia Scortegagna; Kan Ding; Quiyang Zhang; Yavuz Oktay; Michael J Bennett; Michael Bennett; John M Shelton; James A Richardson; Orson Moe; Joseph A Garcia
Journal:  Blood       Date:  2004-12-30       Impact factor: 22.113

Review 7.  Congenital polycythemias/erythrocytoses.

Authors:  Victor R Gordeuk; David W Stockton; Josef T Prchal
Journal:  Haematologica       Date:  2005-01       Impact factor: 9.941

8.  Mutations in the von Hippel-Lindau (VHL) tumor suppressor gene and VHL-haplotype analysis in patients with presumable congenital erythrocytosis.

Authors:  Holger Cario; Klaus Schwarz; Norbert Jorch; Ulrike Kyank; Petro E Petrides; Dominik T Schneider; Renate Uhle; Klaus-Michael Debatin; Elisabeth Kohne
Journal:  Haematologica       Date:  2005-01       Impact factor: 9.941

9.  Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway.

Authors:  J B Hogenesch; W K Chan; V H Jackiw; R C Brown; Y Z Gu; M Pray-Grant; G H Perdew; C A Bradfield
Journal:  J Biol Chem       Date:  1997-03-28       Impact factor: 5.157

10.  Enhancer element at the 3'-flanking region controls transcriptional response to hypoxia in the human erythropoietin gene.

Authors:  I Beck; S Ramirez; R Weinmann; J Caro
Journal:  J Biol Chem       Date:  1991-08-25       Impact factor: 5.157

View more
  117 in total

1.  Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia.

Authors:  Charline Ladroue; David Hoogewijs; Sophie Gad; Romain Carcenac; Federica Storti; Michel Barrois; Anne-Paule Gimenez-Roqueplo; Michel Leporrier; Nicole Casadevall; Olivier Hermine; Jean-Jacques Kiladjian; André Baruchel; Fadi Fakhoury; Brigitte Bressac-de Paillerets; Jean Feunteun; Nathalie Mazure; Jacques Pouysségur; Roland H Wenger; Stéphane Richard; Betty Gardie
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

2.  CYSL-1 interacts with the O2-sensing hydroxylase EGL-9 to promote H2S-modulated hypoxia-induced behavioral plasticity in C. elegans.

Authors:  Dengke K Ma; Roman Vozdek; Nikhil Bhatla; H Robert Horvitz
Journal:  Neuron       Date:  2012-03-08       Impact factor: 17.173

Review 3.  A mechanistic link between renal ischemia and fibrosis.

Authors:  Tetsuhiro Tanaka
Journal:  Med Mol Morphol       Date:  2016-07-20       Impact factor: 2.309

4.  Low oxygen stimulates the intellect. Symposium on hypoxia and development, physiology and disease.

Authors:  Constantinos Koumenis; Patrick H Maxwell
Journal:  EMBO Rep       Date:  2006-07       Impact factor: 8.807

5.  Is congenital secondary erythrocytosis/polycythemia caused by activating mutations within the HIF-2 alpha iron-responsive element?

Authors:  Melanie J Percy; Mayka Sanchez; Sabina Swierczek; Mary Frances McMullin; Mariluz P Mojica-Henshaw; Martina U Muckenthaler; Josef T Prchal; Matthias W Hentze
Journal:  Blood       Date:  2007-10-01       Impact factor: 22.113

6.  A novel erythrocytosis-associated PHD2 mutation suggests the location of a HIF binding groove.

Authors:  Melanie J Percy; Paul W Furlow; Philip A Beer; Terence R J Lappin; Mary Frances McMullin; Frank S Lee
Journal:  Blood       Date:  2007-06-19       Impact factor: 22.113

7.  Erythrocytosis associated with a novel missense mutation in the HIF2A gene.

Authors:  Richard van Wijk; Scott Sutherland; Annet C W Van Wesel; Eric G Huizinga; Melanie J Percy; Marc Bierings; Frank S Lee
Journal:  Haematologica       Date:  2009-12-08       Impact factor: 9.941

Review 8.  Erythropoietin.

Authors:  H Franklin Bunn
Journal:  Cold Spring Harb Perspect Med       Date:  2013-03-01       Impact factor: 6.915

9.  First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia-paraganglioma syndrome.

Authors:  David Taïeb; Chunzhang Yang; Blandine Delenne; Zhengping Zhuang; Anne Barlier; Fréderic Sebag; Karel Pacak
Journal:  J Clin Endocrinol Metab       Date:  2013-03-28       Impact factor: 5.958

10.  In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas.

Authors:  Rodrigo A Toledo; Yuejuan Qin; Subramanya Srikantan; Nicole Paes Morales; Qun Li; Yilun Deng; Sang-Woo Kim; Maria Adelaide A Pereira; Sergio P A Toledo; Xiaoping Su; Ricardo C T Aguiar; Patricia L M Dahia
Journal:  Endocr Relat Cancer       Date:  2013-05-21       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.